Related references
Note: Only part of the references are listed.Future of convection-enhanced delivery in the treatment of brain tumors
Dani S. Bidros et al.
FUTURE ONCOLOGY (2010)
Trial design for evaluation of novel targeted therapies
John Farley et al.
GYNECOLOGIC ONCOLOGY (2010)
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wenting Wu et al.
NEURO-ONCOLOGY (2010)
Optimising the design of phase II oncology trials: The importance of randomisation
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal et al.
CANCER (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Endpoints for assessing drug activity in clinical trials
Richard Pazdur
ONCOLOGIST (2008)
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group
Sandeep Kunwar et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies
Peter Hau et al.
OLIGONUCLEOTIDES (2007)
A clinical development paradigm for cancer vaccines and related biologics
Axel Hoos et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
KH Schlingensiepen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Patterns of care for adults with newly diagnosed malignant glioma
SM Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety
R Schlingensiepen et al.
OLIGONUCLEOTIDES (2005)
Temozolomide in the treatment of recurrent malignant glioma
SM Chang et al.
CANCER (2004)
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
KR Lamborn et al.
NEURO-ONCOLOGY (2004)
Share Paper
